The Food and Drug Omnibus Reform Act

Mr. Aditya Narayan, a student at Stanford University School of Medicine, in Palo Alto, CA, highlights his article appearing in the June 2024 issue of Mayo Clinic Proceedings, regarding provisions in the Food and Drug Omnibus Reform Act - FDORA- which are designed to promote clinical trial diversity, revise the accelerated approval process, modernize clinical trial operations, update marketing exclusivities, expand cosmetics regulations, and fortify infant formula oversight. He notes this initiative promises to increase participation in trials and enhance patient safety and confidence. Available at: mayocl.in/3vL44NK